See more : Toll Brothers, Inc. (0LFS.L) Income Statement Analysis – Financial Results
Complete financial analysis of InnoCan Pharma Corporation (INNPF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of InnoCan Pharma Corporation, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Axial Retailing Inc. (8255.T) Income Statement Analysis – Financial Results
- Beijing Kingfore HV & Energy Conservation Technology Co.,Ltd. (001210.SZ) Income Statement Analysis – Financial Results
- Spey Resources Corp. (SPEY.CN) Income Statement Analysis – Financial Results
- HiTech Group Australia Limited (HIT.AX) Income Statement Analysis – Financial Results
- Comstock Inc. (LODE) Income Statement Analysis – Financial Results
InnoCan Pharma Corporation (INNPF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://innocanpharma.com
About InnoCan Pharma Corporation
InnoCan Pharma Corporation, a pharmaceutical company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Poland, France, and internationally. The company engages in the research and development of COVID-19 and other condition treatment by using CBD loaded exosomes; and CBD loaded liposomes. Its product includes CBD eye serum, CBD face oil, CBD face cream, CBD facial serum, CBD sleeping mask, CBD recovery lotion, and the Relief & Go spray. The company is also involved in the commercialization and sale of branded CBD integrated pharmaceutical and topical treatment products. InnoCan Pharma Corporation was incorporated in 2018 and is headquartered in Calgary, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 13.66M | 2.56M | 196.00K | 8.00K | 0.00 | 0.00 |
| Cost of Revenue | 1.68M | 452.00K | 75.00K | 5.00K | 23.53K | 0.00 |
| Gross Profit | 11.98M | 2.11M | 121.00K | 3.00K | -23.53K | 0.00 |
| Gross Profit Ratio | 87.71% | 82.34% | 61.73% | 37.50% | 0.00% | 0.00% |
| Research & Development | 1.80M | 1.53M | 1.40M | 1.37M | 368.00K | 534.00K |
| General & Administrative | 3.08M | 3.98M | 3.71M | 2.90M | 2.44M | 593.00K |
| Selling & Marketing | 10.91M | 2.86M | 2.50M | 337.00K | 194.00K | 39.00K |
| SG&A | 13.99M | 6.85M | 6.20M | 3.24M | 2.63M | 632.00K |
| Other Expenses | -7.61M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.18M | 8.37M | 7.60M | 4.73M | 3.00M | 1.17M |
| Cost & Expenses | 9.85M | 8.83M | 7.68M | 4.73M | 3.00M | 1.17M |
| Interest Income | 23.42K | 21.00K | 13.00K | 8.00K | 40.00K | 0.00 |
| Interest Expense | 0.00 | 2.00K | 13.00K | 5.23M | 334.00K | 26.00K |
| Depreciation & Amortization | 33.61K | 33.61K | 42.62K | 42.11K | 23.53K | 2.00M |
| EBITDA | -3.77M | -3.70M | -7.44M | -4.69M | -2.98M | 0.00 |
| EBITDA Ratio | -27.60% | -242.67% | -3,794.39% | -58,562.50% | 0.00% | 0.00% |
| Operating Income | 3.80M | -6.27M | -7.48M | -4.73M | -3.00M | -1.17M |
| Operating Income Ratio | 27.85% | -244.86% | -3,816.33% | -59,062.50% | 0.00% | 0.00% |
| Total Other Income/Expenses | -7.84M | 2.38M | -2.61M | -5.23M | -334.00K | 806.86K |
| Income Before Tax | -4.03M | -3.89M | -10.09M | -9.95M | -3.34M | -1.19M |
| Income Before Tax Ratio | -29.54% | -151.93% | -5,148.47% | -124,412.50% | 0.00% | 0.00% |
| Income Tax Expense | 214.00K | 1.00K | -31.00K | -166.30K | -148.86K | -161.14K |
| Net Income | -4.70M | -3.76M | -10.05M | -9.95M | -3.34M | -1.19M |
| Net Income Ratio | -34.41% | -147.09% | -5,126.02% | -124,412.50% | 0.00% | 0.00% |
| EPS | -0.02 | -0.02 | -0.04 | -0.06 | -0.02 | -0.01 |
| EPS Diluted | -0.02 | -0.02 | -0.04 | -0.06 | -0.02 | -0.01 |
| Weighted Avg Shares Out | 257.01M | 248.95M | 224.54M | 162.02M | 143.87M | 143.87M |
| Weighted Avg Shares Out (Dil) | 257.00M | 248.95M | 224.54M | 162.02M | 143.87M | 143.87M |
Innocan Pharma Announces Successful Production of CBD Loaded Liposomes under Aseptic Conditions
Innocan Pharma Successfully Completes Large Scale Production of Exosomes
Innocan Pharma Announces the Launch of Its Commercial Website
Innocan Pharma Announces the Successful Completion of Its First Full-Scale Manufacturing Run in Europe and the Commencement of Its Full-Scale Manufacturing Run in the USA
Source: https://incomestatements.info
Category: Stock Reports